GLP-1 RA Cessation and Gastric Ultrasound Findings
Key facts
- Who runs it
- Wonkwang University Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 186 people enrolled
- Started
- 1 Jul 2026
- Ended
- 4 Aug 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- GLP-1 RA Cessation Interval
- Record updated
- 5 August 2026
Who can take part
- Age
- 19 years to 65 years
- Sex
- Women and men
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Adults aged 18 years or older
- Patients receiving a glucagon-like peptide-1 receptor agonist
- Patients scheduled for elective non-cardiac surgery requiring general anesthesia
- Patients able to provide written informed consent
Who cannot take part
- Emergency surgery
- History of prior gastric surgery
- Known gastroparesis or severe gastroesophageal reflux disease
- Declined or unable to provide written informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery. Adult patients receiving GLP-1 RAs and scheduled for elective non-cardiac surgery under general anesthesia will undergo preoperative point-of-care gastric ultrasound. The study will assess whether longer GLP-1 RA cessation intervals are associated with lower ultrasound-estimated gastric volume and a lower frequency of high-risk gastric contents. Body mass index will also be evaluated as a potential modifier of this association.
The 3 groups in the trial
- Last GLP-1 RA Dose 3 Days or Less
Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 3 days or less before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.
Treatment: GLP-1 RA Cessation Interval
- Last GLP-1 RA Dose 4 to 7 Days
Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 4 to 7 days before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.
Treatment: GLP-1 RA Cessation Interval
- Last GLP-1 RA Dose 8 Days or More
Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 8 days or more before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.
Treatment: GLP-1 RA Cessation Interval
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Time-dependent Association Between Cessation of Glucagon-like Peptide-1 Receptor Agonists and Residual Gastric Contents Assessed by Point-of-care Gastric Ultrasound: a Prospective Observational Study
- Record updated
- 5 August 2026